American Society of Hematology

Figure 5

$Figure 5. Nutlin-3a treatment reduces CXCL12 expression in MSCs and may affects CXCL12/CXCR4 signaling in AML cells. (A) MSCs from 3 normal subjects were treated for 24 hours with 10μM Nutlin-3a, and transcripts were quantitated by real-time PCR. Each real-time PCR was performed in duplicate, and the average fold induction relative to untreated cells is shown. (B) MSCs from 5 normal subjects (N-MSC) were cultured for 48 hours in the presence or absence of 10μM Nutlin-3a, and CXCL12 concentrations in the culture medium were determined. Results are expressed as mean ± SEM (C-D) MOLM-13 cells were treated with 800nM FI-700, 1 ng/mL CXCL12 and 200μM AMD3100 for 24 hours in the presence or absence of MSCs, and annexin V–positive fractions were measured. In some cases, MSCs were pretreated with 10μM Nutlin-3a (N3a) for 24 hours. Asterisk (*) indicates significance at P < .05.$

Nutlin-3a treatment reduces CXCL12 expression in MSCs and may affects CXCL12/CXCR4 signaling in AML cells. (A) MSCs from 3 normal subjects were treated for 24 hours with 10μM Nutlin-3a, and transcripts were quantitated by real-time PCR. Each real-time PCR was performed in duplicate, and the average fold induction relative to untreated cells is shown. (B) MSCs from 5 normal subjects (N-MSC) were cultured for 48 hours in the presence or absence of 10μM Nutlin-3a, and CXCL12 concentrations in the culture medium were determined. Results are expressed as mean ± SEM (C-D) MOLM-13 cells were treated with 800nM FI-700, 1 ng/mL CXCL12 and 200μM AMD3100 for 24 hours in the presence or absence of MSCs, and annexin V–positive fractions were measured. In some cases, MSCs were pretreated with 10μM Nutlin-3a (N3a) for 24 hours. Asterisk (*) indicates significance at P < .05.

This Feature Is Available To Subscribers Only